Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus tegafur and nab-paclitaxel versus tegafur and nab-paclitaxel as neoadjuvant therapy for resectable/locally advanced pancreatic cancer
ChiCTR1800020401Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib, tegafur and nab-paclitaxel in pancreatic cancer (PC) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: overall survival. Started Jan 2019; status: recruiting.
02
Drugs
Rivoceranibtegafurnab-paclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR1800020401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020401.